Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2649
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response ; day:19 ; month:5 ; year:2021 ; pages:1-9
Quality of life research ; (19.5.2021), 1-9
- Creator
-
Miyasaka, Akio
Yoshida, Yuichi
Suzuki, Akiko
Takikawa, Yasuhiro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11136-021-02874-6
- URN
-
urn:nbn:de:101:1-2021091809314629335057
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miyasaka, Akio
- Yoshida, Yuichi
- Suzuki, Akiko
- Takikawa, Yasuhiro
- SpringerLink (Online service)
Other Objects (12)
Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response
A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation
Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained virological suppression
Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
Effect of achieving sustained virological response with direct-acting antiviral agents on glycemic control in diabetic patients with chronic hepatitis C infection
Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression
Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response
A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation
Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained virological suppression
Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
Effect of achieving sustained virological response with direct-acting antiviral agents on glycemic control in diabetic patients with chronic hepatitis C infection
Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression
Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response
A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation
Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained virological suppression
Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
Effect of achieving sustained virological response with direct-acting antiviral agents on glycemic control in diabetic patients with chronic hepatitis C infection
Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression
Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response